Nordea Investment Management AB grew its stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Get Rating) by 17.8% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 8,547 shares of the biopharmaceutical company’s stock after acquiring an additional 1,293 shares during the quarter. Nordea Investment Management AB’s holdings in Alnylam Pharmaceuticals were worth $2,017,000 as of its most recent SEC filing.
A number of other hedge funds and other institutional investors have also modified their holdings of the stock. Nwam LLC acquired a new stake in shares of Alnylam Pharmaceuticals in the 4th quarter worth $202,000. Arizona State Retirement System grew its holdings in shares of Alnylam Pharmaceuticals by 2.4% during the 4th quarter. Arizona State Retirement System now owns 33,974 shares of the biopharmaceutical company’s stock worth $8,074,000 after purchasing an additional 803 shares during the period. Toronto Dominion Bank grew its holdings in shares of Alnylam Pharmaceuticals by 37.0% during the 4th quarter. Toronto Dominion Bank now owns 36,670 shares of the biopharmaceutical company’s stock worth $8,709,000 after purchasing an additional 9,911 shares during the period. Commonwealth Equity Services LLC grew its holdings in shares of Alnylam Pharmaceuticals by 9.1% during the 4th quarter. Commonwealth Equity Services LLC now owns 5,207 shares of the biopharmaceutical company’s stock worth $1,237,000 after purchasing an additional 433 shares during the period. Finally, Benjamin F. Edwards & Company Inc. purchased a new position in shares of Alnylam Pharmaceuticals during the 4th quarter worth $314,000.
Insiders Place Their Bets
In other Alnylam Pharmaceuticals news, CEO Yvonne Greenstreet sold 7,615 shares of Alnylam Pharmaceuticals stock in a transaction that occurred on Thursday, April 27th. The stock was sold at an average price of $194.59, for a total value of $1,481,802.85. Following the transaction, the chief executive officer now directly owns 30,332 shares in the company, valued at approximately $5,902,303.88. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In other Alnylam Pharmaceuticals news, CFO Jeffrey V. Poulton sold 977 shares of Alnylam Pharmaceuticals stock in a transaction that occurred on Thursday, April 27th. The stock was sold at an average price of $194.59, for a total value of $190,114.43. Following the transaction, the chief financial officer now directly owns 11,706 shares in the company, valued at approximately $2,277,870.54. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Yvonne Greenstreet sold 7,615 shares of Alnylam Pharmaceuticals stock in a transaction that occurred on Thursday, April 27th. The shares were sold at an average price of $194.59, for a total value of $1,481,802.85. Following the completion of the transaction, the chief executive officer now owns 30,332 shares in the company, valued at $5,902,303.88. The disclosure for this sale can be found here. Insiders have sold a total of 35,871 shares of company stock valued at $7,131,842 over the last quarter. Company insiders own 1.40% of the company’s stock.
Analyst Upgrades and Downgrades
Alnylam Pharmaceuticals Stock Down 0.4 %
ALNY opened at $205.36 on Friday. The firm has a market cap of $25.57 billion, a price-to-earnings ratio of -23.63 and a beta of 0.48. Alnylam Pharmaceuticals, Inc. has a 52 week low of $120.43 and a 52 week high of $242.97. The business’s 50 day moving average is $198.66 and its two-hundred day moving average is $212.77.
Alnylam Pharmaceuticals (NASDAQ:ALNY – Get Rating) last released its quarterly earnings results on Thursday, May 4th. The biopharmaceutical company reported ($1.40) EPS for the quarter, topping the consensus estimate of ($1.97) by $0.57. The company had revenue of $319.29 million for the quarter, compared to analyst estimates of $312.53 million. Alnylam Pharmaceuticals had a negative return on equity of 1,287.80% and a negative net margin of 93.13%. The firm’s revenue was up 49.7% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($2.00) earnings per share. Equities analysts expect that Alnylam Pharmaceuticals, Inc. will post -7.05 EPS for the current fiscal year.
Alnylam Pharmaceuticals Profile
Alnylam Pharmaceuticals, Inc is a global commercial-stage biopharmaceutical company, which engages in the discovery, development and commercialization of RNAi therapeutics. Its products include ONPATTRO, GIVLAARI, and OXLUMO. The company was founded by Noble Laureate, David Bartel, Thomas Tuschl, Phillip Zamore, Paul R.
Featured Articles
- Get a free copy of the StockNews.com research report on Alnylam Pharmaceuticals (ALNY)
- An Updraft Is Brewing For DraftKings
- PepsiCo Hits “Sweet Spot” For APAC Growth, Macros Agree
- High-Risk Mullen Automotive Continues To Build Momentum
- 3 Recession-Proof Stocks With Nice Dividends
- Oracle Stock Climbs For Third Month, Still In Buy Range
Want to see what other hedge funds are holding ALNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Get Rating).
Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
